稳心颗粒联合美托洛尔对冠心病合并室性心律失常的治疗效果  

The therapeutic effect of Wenxin granules combined with metoprolol on coronary heart disease complicated with ventricular arrhythmias

作　　者：莫介超 MO Jie-chao(Yangchun People's Hospital,Yangchun 529600,China)

机构地区：[1]阳春市人民医院,529600

出　　处：《中国实用医药》2025年第1期84-87,共4页China Practical Medicine

摘　　要：目的分析稳心颗粒联合美托洛尔对冠心病合并室性心律失常患者的治疗效果。方法68例冠心病合并室性心律失常患者,依据双盲分组方式分为研究组、对照组,每组34例。对照组选择美托洛尔治疗,研究组选择稳心颗粒联合美托洛尔治疗。比较两组缺血、心律失常情况,心电图指标,心功能指标,血液流变学指标,治疗效果。结果治疗后,研究组患者缺血发生次数(2.11±0.54)次/d、心律失常发生次数(1.28±0.43)次/d较对照组的(6.08±1.80)、(2.73±0.91)次/d更少,缺血持续时间(2.96±1.19)min/次及心律失常持续时间(10.02±1.72)s/次较对照组的(6.41±1.64)min/次、(19.63±3.84)s/次更短,差异具统计价值(P<0.05)。治疗后,研究组短阵室性心动过速、室性期前收缩次数较对照组更少,ST段下降持续时间较对照组更短,差异具统计价值(P<0.05)。治疗后,研究组左室射血分数(41.18±7.20)%、心输出量(4.58±0.79)L/min较对照组的(35.56±6.03)%、(4.01±0.56)L/min更高,左室收缩末期内径(43.29±4.11)mm较对照组的(51.82±5.80)mm更短,差异具统计价值(P<0.05)。治疗后,研究组血浆粘度(1.11±0.05)mPa·s、血细胞比容(39.98±1.94)%、纤维蛋白原(2.10±0.08)g/L较对照组的(1.74±0.10)mPa·s、(43.25±2.03)%、(3.97±0.15)g/L明显降低,差异具统计价值(P<0.05)。研究组治疗总有效率97.06%远高于对照组的79.41%,差异具统计价值(P<0.05)。结论冠心病合并室性心律失常患者经稳心颗粒联合美托洛尔治疗后疗效显著,切实减轻心律失常症状表现,改善病情,应在临床治疗中予以推广使用。Objective To analyze the therapeutic effect of Wenxin granules combined with metoprolol on coronary heart disease complicated with ventricular arrhythmias.Methods 68 patients with coronary heart disease complicated with ventricular arrhythmia were divided into a study group and a control group according to a double-blind grouping method,each consisting of 34 cases.The control group received metoprolol treatment,while the study group received combined treatment of Wenxin granules and metoprolol.The ischemic and arrhythmic conditions,electrocardiogram indicators,cardiac function indicators,hemorheological indicators,and treatment effects were compared between the two groups.Results After treatment,the frequency of ischemia and arrhythmia in the study group were(2.11±0.54)and(1.28±0.43)times/d,which were lower than(6.08±1.80)and(2.73±0.91)times/d in the control group;the duration of ischemia and arrhythmia in the study group were(2.96±1.19)min/time and(10.02±1.72)s/time,which were shorter than(6.41±1.64)min/time and(19.63±3.84)s/time in the control group;the difference was statistically valuable(P<0.05).After treatment,the study group had fewer non-sustained ventricular tachycardia and ventricular preterm contractions than those in the control group,and the duration of ST segment depression was shorter than that in the control group.The difference was statistically valuable(P<0.05).After treatment,the left ventricular ejection fraction and cardiac output were(41.18±7.20)%and(4.58±0.79)L/min in the study group,which were higher than(35.56±6.03)%and(4.01±0.56)L/min in the control group;the study group had shorter left ventricular end-systolic diameter of(43.29±4.11)mm than(51.82±5.80)mm in the control group;the difference was statistically valuable(P<0.05).After treatment,in the study group,the plasma viscosity was(1.11±0.05)mPa·s,the hematocrit was(39.98±1.94)%,and the fibrinogen was(2.10±0.08)g/L,which were significantly lower than(1.74±0.10)mPa·s,(43.25±2.03)%,and(3.97±0.15)g/L in the control

关 键 词：冠心病 室性心律失常 稳心颗粒 美托洛尔 

分 类 号：R541.7[医药卫生—心血管疾病] R541.4[医药卫生—内科学]